Genetic variation in the HSD17B1 gene and risk of prostate cancer - PubMed (original) (raw)
doi: 10.1371/journal.pgen.0010068. Epub 2005 Nov 25.
Paul Pharoah, Stephen J Chanock, Demetrius Albanes, Laurence N Kolonel, Richard B Hayes, David Altshuler, Gerald Andriole, Christine Berg, Heiner Boeing, Noel P Burtt, Bas Bueno-de-Mesquita, Eugenia E Calle, Howard Cann, Federico Canzian, Yen-Ching Chen, David E Crawford, Alison M Dunning, Heather S Feigelson, Matthew L Freedman, John M Gaziano, Ed Giovannucci, Carlos Alberto Gonzalez, Christopher A Haiman, Goran Hallmans, Brian E Henderson, Joel N Hirschhorn, David J Hunter, Rudolf Kaaks, Timothy Key, Loic Le Marchand, Jing Ma, Kim Overvad, Domenico Palli, Malcolm C Pike, Elio Riboli, Carmen Rodriguez, Wendy V Setiawan, Meir J Stampfer, Daniel O Stram, Gilles Thomas, Michael J Thun, Ruth Travis, Antonia Trichopoulou, Jarmo Virtamo, Sholom Wacholder
Affiliations
- PMID: 16311626
- PMCID: PMC1287955
- DOI: 10.1371/journal.pgen.0010068
Genetic variation in the HSD17B1 gene and risk of prostate cancer
Peter Kraft et al. PLoS Genet. 2005 Nov.
Abstract
Steroid hormones are believed to play an important role in prostate carcinogenesis, but epidemiological evidence linking prostate cancer and steroid hormone genes has been inconclusive, in part due to small sample sizes or incomplete characterization of genetic variation at the locus of interest. Here we report on the results of a comprehensive study of the association between HSD17B1 and prostate cancer by the Breast and Prostate Cancer Cohort Consortium, a large collaborative study. HSD17B1 encodes 17beta-hydroxysteroid dehydrogenase 1, an enzyme that converts dihydroepiandrosterone to the testosterone precursor Delta5-androsterone-3beta,17beta-diol and converts estrone to estradiol. The Breast and Prostate Cancer Cohort Consortium researchers systematically characterized variation in HSD17B1 by targeted resequencing and dense genotyping; selected haplotype-tagging single nucleotide polymorphisms (htSNPs) that efficiently predict common variants in U.S. and European whites, Latinos, Japanese Americans, and Native Hawaiians; and genotyped these htSNPs in 8,290 prostate cancer cases and 9,367 study-, age-, and ethnicity-matched controls. We found no evidence that HSD17B1 htSNPs (including the nonsynonymous coding SNP S312G) or htSNP haplotypes were associated with risk of prostate cancer or tumor stage in the pooled multiethnic sample or in U.S. and European whites. Analyses stratified by age, body mass index, and family history of disease found no subgroup-specific associations between these HSD17B1 htSNPs and prostate cancer. We found significant evidence of heterogeneity in associations between HSD17B1 haplotypes and prostate cancer across ethnicity: one haplotype had a significant (p < 0.002) inverse association with risk of prostate cancer in Latinos and Japanese Americans but showed no evidence of association in African Americans, Native Hawaiians, or whites. However, the smaller numbers of Latinos and Japanese Americans in this study makes these subgroup analyses less reliable. These results suggest that the germline variants in HSD17B1 characterized by these htSNPs do not substantially influence the risk of prostate cancer in U.S. and European whites.
Conflict of interest statement
Competing interests. The authors have declared that no competing interests exist.
Figures
Figure 1. A Scale Map of the 26 SNPs Genotyped in the MEC Screening Panel and a Plot of the Pattern of Linkage Disequilibrium among Them (in Whites)
The four tag SNPs are markers with arrows, and the block of high linkage disequilibrium and limited haplotype diversity spanning HSD17B1 is highlighted.
Figure 2. Plot of Log Odds Ratios for CAGC (Relative to All Other Haplotypes) under an Additive Model
The boxes are proportional to the inverse of the parameter estimate variance; larger boxes denote more precise estimates. The error bars mark 99% confidence intervals.
Similar articles
- Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies.
Feigelson HS, Cox DG, Cann HM, Wacholder S, Kaaks R, Henderson BE, Albanes D, Altshuler D, Berglund G, Berrino F, Bingham S, Buring JE, Burtt NP, Calle EE, Chanock SJ, Clavel-Chapelon F, Colditz G, Diver WR, Freedman ML, Haiman CA, Hankinson SE, Hayes RB, Hirschhorn JN, Hunter D, Kolonel LN, Kraft P, LeMarchand L, Linseisen J, Modi W, Navarro C, Peeters PH, Pike MC, Riboli E, Setiawan VW, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D. Feigelson HS, et al. Cancer Res. 2006 Feb 15;66(4):2468-75. doi: 10.1158/0008-5472.CAN-05-3574. Cancer Res. 2006. PMID: 16489054 - CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.
Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D, Berglund G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Calle EE, Chanock S, Dunning AM, Hayes R, Feigelson HS, Gaziano JM, Giovannucci E, Haiman CA, Henderson BE, Kaaks R, Kolonel LN, Ma J, Rodriguez L, Riboli E, Stampfer M, Stram DO, Thun MJ, Tjønneland A, Trichopoulos D, Vineis P, Virtamo J, Le Marchand L, Hunter DJ. Travis RC, et al. Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2734-44. doi: 10.1158/1055-9965.EPI-09-0496. Epub 2009 Sep 29. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19789370 Free PMC article. - Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D, Altshuler D, Andriole G, Berg CD, Boeing H, Burtt N, Bueno-de-Mesquita B, Cann H, Canzian F, Chanock S, Dunning A, Feigelson HS, Freedman M, Gaziano JM, Giovannucci E, Sánchez MJ, Haiman CA, Hallmans G, Hayes RB, Henderson BE, Hirschhorn J, Kaaks R, Key TJ, Kolonel LN, LeMarchand L, Ma J, Overvad K, Palli D, Pharaoh P, Pike M, Riboli E, Rodriguez C, Setiawan VW, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC, Virtamo J, Trichopoulou A, Wacholder S, Weinstein SJ. Chen YC, et al. Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1973-81. doi: 10.1158/1055-9965.EPI-07-0431. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17932344 - Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review.
Olson SH, Bandera EV, Orlow I. Olson SH, et al. Am J Epidemiol. 2007 Feb 1;165(3):235-45. doi: 10.1093/aje/kwk015. Epub 2006 Nov 16. Am J Epidemiol. 2007. PMID: 17110639 Review. - Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression.
Makridakis NM, Reichardt JK. Makridakis NM, et al. J Urol. 2004 Feb;171(2 Pt 2):S25-8; discussion S28-9. doi: 10.1097/01.ju.0000107844.78769.35. J Urol. 2004. PMID: 14713749 Review.
Cited by
- Genetic variants in CYP2B6 and HSD17B12 associated with risk of squamous cell carcinoma of the head and neck.
Liu H, Li G, Sturgis EM, Shete S, Dahlstrom KR, Du M, Amos CI, Christiani DC, Lazarus P, Wei Q. Liu H, et al. Int J Cancer. 2022 Aug 15;151(4):553-564. doi: 10.1002/ijc.34023. Epub 2022 May 7. Int J Cancer. 2022. PMID: 35404482 Free PMC article. - Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients.
Wu X, Xu QJ, Chen PZ, Yu CB, Ye LF, Li T. Wu X, et al. Pharmgenomics Pers Med. 2020 Jun 4;13:181-188. doi: 10.2147/PGPM.S245086. eCollection 2020. Pharmgenomics Pers Med. 2020. PMID: 32581567 Free PMC article. - Association of 17q24 rs1859962 gene polymorphism with prostate cancer risk: A systematic review and meta-analysis.
Ren F, Zhang P, Ma Z, Zhang L, Li G, Huang X, Chang D, Yu X. Ren F, et al. Medicine (Baltimore). 2020 Jan;99(3):e18398. doi: 10.1097/MD.0000000000018398. Medicine (Baltimore). 2020. PMID: 32011434 Free PMC article. - Epidemiology of Prostate Cancer.
Rawla P. Rawla P. World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20. World J Oncol. 2019. PMID: 31068988 Free PMC article. Review. - Investigation of the Best Saccharomyces cerevisiae Growth Condition.
Salari R, Salari R. Salari R, et al. Electron Physician. 2017 Jan 25;9(1):3592-3597. doi: 10.19082/3592. eCollection 2017 Jan. Electron Physician. 2017. PMID: 28243411 Free PMC article.
References
- Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004;13((Spec No 1)):R103–R121. - PubMed
- Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, et al. Prostate cancer susceptibility genes: Lessons learned and challenges posed. Endocr Relat Cancer. 2003;10:225–259. - PubMed
- Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Cancer. 2003;107:797–803. - PubMed
- Houlston R, Peto J. Genetics and the common cancers. In: Eeles R, Ponder B, Easton D, Eng C, editors. Genetic predisposition to cancer. London: Chapman & Hall; 2004. pp. 235–247.
- Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, et al. Environmental and heritable factors in the causation of cancer—Analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med. 2000;343:78–85. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UO1-CA98758/CA/NCI NIH HHS/United States
- U01 CA098216/CA/NCI NIH HHS/United States
- UO1-CA98233/CA/NCI NIH HHS/United States
- UO1-CA98216/CA/NCI NIH HHS/United States
- U01 CA098233/CA/NCI NIH HHS/United States
- U01 CA098758/CA/NCI NIH HHS/United States
- UO1-CA98710/CA/NCI NIH HHS/United States
- R01 CA097193/CA/NCI NIH HHS/United States
- U01 CA098710/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical